The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway

Glycobiology

Volumn 23, Issue 2, 2013, Pages 178-187

  Takamiya, Rina ^a   Ohtsubo, Kazuaki ^a   Takamatsu, Shinji ^a   Taniguchi, Naoyuki ^a,b   Angata, Takashi ^a  

^a RIKEN   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

DNAX activation protein of 12 kDa; macrophages sialyl Tn antigen; Siglec 15; transforming growth factor

Indexed keywords

COLONY STIMULATING FACTOR; KILLER CELL ACTIVATING RECEPTOR ASSOCIATED PROTEIN; PROTEIN KINASE SYK; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC 15; TN ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ASSOCIATED SIALYL TN ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HUMANS; IMMUNOGLOBULINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MACROPHAGES; MEMBRANE PROTEINS; MONOCYTES; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84872001426     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cws139     Document Type: Article

References (44)

1. Aarnoudse CA, Garcia Vallejo JJ, Saeland E, van Kooyk Y. 2006. Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol. 18: 105-111.
2. Angata T, Fujinawa R, Kurimoto A, Nakajima K, Kato M, Takamatsu S, Korekane H, Gao CX, Ohtsubo K, Kitazume S, et al. 2012. Integrated approach toward the discovery of glyco-biomarkers of inflammation-related diseases. Ann N Y Acad Sci. 1253: 159-169.
3. Angata T, Tabuchi Y, Nakamura K, Nakamura M. 2007. Siglec-15: An immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 17: 838-846.
4. Bresalier RS, Ho SB, Schoeppner HL, Kim YS, Sleisenger MH, Brodt P, Byrd JC. 1996. Enhanced sialylation of mucin-associated carbohydrate structures in human colon cancer metastasis. Gastroenterology. 110: 1354-1367.
5. Brockhausen I. 2006. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 7: 599-604.
6. Crocker PR, Varki A. 2001. Siglecs, sialic acids and innate immunity. Trends Immunol. 22: 337-342.
7. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. 2010. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 10: 554-567.
8. Fukuda M. 1991. Leukosialin, a major O-glycan-containing sialoglycoprotein defining leukocyte differentiation and malignancy. Glycobiology. 1: 347-356.
9. Graham LM, Gupta V, Schafer G, Reid DM, Kimberg M, Dennehy KM, Hornsell WG, Guler R, Campanero-Rhodes MA, Palma AS, et al. 2012. The C-type lectin receptor CLECSF8 (CLEC4D) is expressed by myeloid cells and triggers cellular activation through Syk Kinase. J Biol Chem. 287: 25964-25974.
10. Holmberg LA, Oparin DV, Gooley T, Lilleby K, Bensinger W, Reddish MA, MacLean GD, Longenecker BM, Sandmaier BM. 2000. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 25: 1233-1241.
11. Humphrey MB, Lanier LL, Nakamura MC. 2005. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev. 208: 50-65.
12. Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, Yamashina I, Inoue M, Nakada H. 2003. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci USA. 100: 2736-2741.
13. Ishida-Kitagawa N, Tanaka K, Bao X, Kimura T, Miura T, Kitaoka Y, Hayashi K, Sato M, Maruoka M, Ogawa T, et al. 2012. Siglec-15 regulates the formation of functional osteoclasts in concert with DNAX-activating protein of 12 KDa (DAP12). J Biol Chem. 287: 17493-17502.
14. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS. 1990. Sialosyl-Tn: A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer. 66: 1960-1966.
15. Kakeji Y, Maehara Y, Morita M, Matsukuma A, Furusawa M, Takahashi I, Kusumoto T, Ohno S, Sugimachi K. 1995. Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. Br J Cancer. 71: 191-195.
16. Kannagi R, Sakuma K, Miyazaki K, Lim KT, Yusa A, Yin J, Izawa M. 2010. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: Clues in the ongoing search for new tumor markers. Cancer Sci. 101: 586-593.
17. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T, Kumagai H. 2003. Retrovirus-mediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol. 31: 1007-1014.
18. Korekane H, Matsumoto A, Ota F, Hasegawa T, Misonou Y, Shida K, Miyamoto Y, Taniguchi N. 2010. Involvement of ST6Gal I in the biosynthesis of a unique human colon cancer biomarker candidate, alpha2,6-sialylated blood group type 2H (ST2H) antigen. J Biochem. 148: 359-370.
19. Lanier LL. 2009. DAP10-and DAP12-associated receptors in innate immunity. Immunol Rev. 227: 150-160.
20. Lin EY, Nguyen AV, Russell RG, Pollard JW. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 193: 727-740.
21. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23: 549-555.
22. Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, et al. 2011. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 16: 1092-1100.
23. Miles DW, Linehan J, Smith P, Filipe I. 1995. Expression of sialyl-Tn in gastric cancer: Correlation with known prognostic factors. Br J Cancer. 71: 1074-1076.
24. Miyazaki K, Ohmori K, Izawa M, Koike T, Kumamoto K, Furukawa K, Ando T, Kiso M, Yamaji T, Hashimoto Y, et al. 2004. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 64: 4498-4505.
25. Miyazaki K, Sakuma K, Kawamura YI, Izawa M, Ohmori K, Mitsuki M, Yamaji T, Hashimoto Y, Suzuki A, Saito Y, et al. 2012. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors Siglec-7 and-9. J Immunol. 188: 4690-4700.
26. Nakagoe T, Nanashima A, Sawai T, Tuji T, Yamaguchi E, Jibiki M, Yamaguchi H, Yasutake T, Ayabe H, Matuo T, et al. 2000. Different expression of sialyl Tn antigen between polypoid and nonpolypoid growth types of advanced colorectal carcinoma. Oncology. 59: 131-138.
27. Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K, Ishikawa H. 2002. Predictive factors for preoperative serum levels of sialy Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res. 22: 451-458.
28. Nowicki A, Szenajch J, Ostrowska G, Wojtowicz A, Wojtowicz K, Kruszewski AA, Maruszynski M, Aukerman SL, Wiktor-Jedrzejczak W. 1996. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophagedeficient op/op mouse: Evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int J Cancer. 65: 112-119.
29. Ohta M, Ishida A, Toda M, Akita K, Inoue M, Yamashita K, Watanabe M, Murata T, Usui T, Nakada H. 2010. Immunomodulation of monocytederived dendritic cells through ligation of tumor-produced mucins to Siglec-9. Biochem Biophys Res Commun. 402: 663-669.
30. Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F, Ratnam M, Sanchez-Mateos P, Corbi AL. 2009. Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 69: 9395-9403.
31. Rabinovich GA, Croci DO. 2012. Regulatory circuits mediated by lectinglycan interactions in autoimmunity and cancer. Immunity. 36: 322-335.
32. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, Miyake T, Matsushita K, Okazaki T, Saitoh T, et al. 2010. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. 11: 936-944.
33. Shabo I, Svanvik J. 2011. Expression of macrophage antigens by tumor cells. Adv Exp Med Biol. 714: 141-150.
34. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. 2008. Macrophage polarization in tumour progression. Semin Cancer Biol. 18: 349-355.
35. Sica A, Mantovani A. 2012. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122: 787-795.
36. Sica A, Schioppa T, Mantovani A, Allavena P. 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer. 42: 717-727.
37. Sierra-Filardi E, Puig-Kroger A, Blanco FJ, Nieto C, Bragado R, Palomero MI, Bernabeu C, Vega MA, Corbi AL. 2011. Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood. 117: 5092-5101.
38. Silver HK, Karim KA, Archibald EL, Salinas FA. 1979. Serum sialic acid and sialyltransferase as monitors of tumor burden in malignant melanoma patients. Cancer Res. 39: 5036-5042.
39. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, Chiabrando C, Mantovani A, et al. 2010. Tumor-conditioned macrophages secrete migration-stimulating factor: A new marker for M2-polarization, influencing tumor cell motility. J Immunol. 185: 642-652.
40. Taniguchi N. 2008. Toward cancer biomarker discovery using the glycomics approach. Proteomics. 8: 3205-3208.
41. Varki A, Angata T. 2006. Siglecs-The major subfamily of I-type lectins. Glycobiology. 16: 1R-27R.
42. Varki NM, Varki A. 2007. Diversity in cell surface sialic acid presentations: Implications for biology and disease. Lab Invest. 87: 851-857.
43. Wang F, Goto M, Kim YS, Higashi M, Imai K, Sato E, Yonezawa S. 2001. Altered GalNAc-alpha-2,6-sialylation compartments for mucin-associated sialyl-Tn antigen in colorectal adenoma and adenocarcinoma. J Histochem Cytochem. 49: 1581-1592.
44. Yasui K, Angata T, Matsuyama N, Furuta RA, Kimura T, Okazaki H, Tani Y, Nakano S, Narimatsu H, Hirayama F. 2011. Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions. Br J Haematol. 153: 794-796.